Home › Scleroderma › Kansas › Kansas City
Scleroderma clinical trials in Kansas City, KS
4 studies for Scleroderma are looking for participants at sites in and around Kansas City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- University of Kansas Cancer Center, Kansas City
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
- University of Kansas Medical Center, Kansas City
Platform Clinical Study for Conquering Scleroderma
RecruitingPhase 2
- University of Kansas School of Medicine, Kansas City
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RecruitingPhase 2/3
- University of Kansas Medical Center, Kansas City
About Scleroderma
Scleroderma is an autoimmune disease that causes inflammation and thickening in the skin and other areas of the body. The exact cause of scleroderma is unknown.
More about Scleroderma on MedlinePlus
Scleroderma trials in other cities
- New York City, NY11 studies
- Ann Arbor, MI10 studies
- Chicago, IL10 studies
- Houston, TX9 studies
- Los Angeles, CA7 studies
- Boston, MA7 studies
- Durham, NC7 studies
- New Orleans, LA6 studies
- Baltimore, MD6 studies
- Philadelphia, PA6 studies
- Dallas, TX5 studies
- Pittsburgh, PA5 studies
Other studies in Kansas City
- Interstitial Lung Diseases14 studies
- Cardiovascular Disease14 studies
- Cystic Fibrosis13 studies
- Obesity13 studies
- Heart Failure13 studies
- Bladder Cancer12 studies
- Prostate Cancer12 studies
- Breast Cancer12 studies
- Lung Cancer11 studies
- Non-Small Cell Lung Cancer11 studies
- Acute Myeloid Leukemia11 studies
- COPD9 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.